key: cord-0952414-eayhxc56
authors: Goren, Andy; Wambier, Carlos Gustavo; Herrera, Sabina; McCoy, John; Vaño‐Galván, Sergio; Gioia, Francesca; Comeche, Belen; Ron, Raquel; Serrano‐Villar, Sergio; Ramos, Paulo Müller; Cadegiani, Flávio Adsuara; Kovacevic, Maja; Tosti, Antonella; Shapiro, Jerry; Sinclair, Rodney
title: Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
date: 2020-09-25
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16953
sha: da9a968a4d5659062a09ef81da035f4c3f7c923f
doc_id: 952414
cord_uid: eayhxc56

The COVID‐19 pandemic has disproportionally affected men.(1) Men infected with SARS‐CoV‐2 are more than twice as likely to be admitted to the intensive care unit (ICU).(2) This disparity in ICU admissions suggests the important role of androgens in COVID‐19 severity.(3) Previously, we reported that among 122 men hospitalized due to COVID‐19, 79% were diagnosed with androgenetic alopecia (AGA),(4) which is commonly treated with anti‐androgens. Anti‐androgens commonly used in the treatment of AGA such as finasteride, dutasteride, spironolactone, and bicalutamide could improve outcomes among men infected by SARS‐CoV‐2.

Dear Editor, The COVID-19 pandemic has disproportionally affected men. 1 Men infected with SARS-CoV-2 are more than twice as likely to be admitted to the intensive care unit (ICU). 2 This disparity in ICU admissions suggests the important role of androgens in COVID-19 severity. 3 Previously, we reported that among 122 men hospitalized due to COVID-19, 79% were diagnosed with androgenetic alopecia (AGA), 4 which is commonly treated with anti-androgens. Anti-androgens commonly used in the treatment of AGA such as finasteride, dutasteride, spironolactone, and bicalutamide could improve outcomes among men infected by SARS-CoV-2.

A prospective cohort study was conducted from the data of men hospitalized due to COVID-19 followed in an observational genetic case-control study (NCT04368897). The subjects were categorized into two cohorts: those taking anti-androgens for at least 6 months or those not taking anti-androgens prior to hospitalization. Enrollment occurred in a sequential order from late March to early May 2020. The subjects were followed for a period of 60 days from the date of hospitalization. The primary outcome was the rate of ICU admission. 77 subjects were included, mean age was 68.6 ±12.7 (Table I) . 12 men (15.6%) were taking antiandrogens: dutasteride (n=9), finasteride (n=2), or spironolactone (n=1). 65 men (84.4%) were not taking anti-androgens. The average age of those taking anti-androgens was higher, 80.6 ±8.2, versus 66.4 ±12.2, p=0.0002. The proportion of subjects admitted to the ICU taking anti-androgens was significantly lower, 1/12 (8%) versus 38/65 (58%), p=0.0015, Figure. 1. Because the age of the subjects taking anti-androgens was skewed older, an age-matched subset (>65 years old) analysis was performed. There were 34 subjects in the age-matched subset with an average age of 75.9 ±8.0.

The ICU admission rate in the age-matched group was 44%. The proportion of subjects admitted to the ICU taking anti-androgens was significantly lower than the proportion of subjects admitted to the ICU in the age-matched subset, p=0.018. The relative risk for ICU admission for subjects taking anti-androgens was (RR 0.14, 95% CI: 0.02-0.94). The relative risk for ICU admission for subjects taking anti-androgens compared to the age-matched group was (RR 0.19, 95%CI: 0.03-1.28). When the patient taking spironolactone was excluded from the analysis, the use of 5-alpha-reductase inhibitors maintained statistical significance for reduced ICU admissions, p=0.0028. Different from all other patients on the anti-androgen cohort, the patient taking spironolactone did not have the

This article is protected by copyright. All rights reserved diagnosis of benign prostate hyperplasia, and was taking it due to cardiovascular reasons (hypertension and congestive heart failure). The rates of diabetes mellitus, obesity, and hypertension (known risk factors for worse outcomes) were similar in all groups.

We recognize the limitations of this small study; however, these results, as well as previous data presented in a retrospective study of androgen deprivation in prostate cancer patients (with stronger anti-androgens such as bicalutamide in association with chemical castration), 5 suggest that anti-androgens may represent a promising treatment modality for COVID-19. Recently, it has been demonstrated that both dutasteride and spironolactone reduce the levels of both angiotensin converting enzyme 2 (ACE2) and TMPRSS2 in embryonic cardiac stem cell model. 6 Madrid, Spain. Individuals were categorized by use of anti-androgens for at least 6 months before hospital admission, and followed for 60 days. The relative risk for intensive care unit (ICU) admission for individuals taking anti-androgens was 0.14 (95% confidence interval: 0.02-0.94).

Table I. Characteristics of the anti-androgen group, and non-anti-androgen groups.

This article is protected by copyright. All rights reserved Table I . Characteristics of the anti-androgen group, and non-anti-androgen groups. 

Sex hormones signal why virus hits men harder

Impact of sex and gender on COVID-19 outcomes in Europe

Androgen sensitivity gateway to COVID-19 disease severity

Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients -the "Gabrin sign

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)

Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men. bioRxiv

Accepted Article